CB-183,315

· Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for CB-183,315, covering 2015-06-16 to 2018-02-28. Get the full timeline:

Most recent: Clinical Trial Update: Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) [Phase 3]